UTMD Q3 EPS Rises 6.8% Despite 12% Sales Drop; Full-Year Decline Trimmed to ~7%
UTMD sits 39% above its 52-week low of $53.66.
Summary
Third-quarter sales fell 12.1% to $8.62 million, but diluted EPS rose 6.8% to $0.876 as the completion of Femcare intangible amortization and lower litigation costs cut G&A sharply. The revenue miss is largely the known loss of two former top customers — PendoTECH and the prior China BPM distributor — which contributed zero in 2026 versus $491 thousand in 3Q 2025. Filshie Clip sales worsened, down 32.7% in the quarter, partly offset by $619 thousand from the Orion Medical acquisition closed in late August. Nine-month EPS of $2.537 is down 5.3% on a 12.2% sales decline. Management now projects a full-year 2026 sales decline of about 7%, a meaningful improvement from the 12% year-to-date drop, implying a much stronger fourth quarter. The balance sheet remains debt-free with $85.2 million in cash and investments. The 10-Q is due in November; two remaining Filshie litigation cases are slated for trial in 2027.
At the time of this announcement, UTMD was trading at $74.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $237.1M. The 52-week trading range was $53.66 to $76.89. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.